Teva and Biolojic enter therapeutic antibody development deal

Teva Pharmaceutical has signed a licence agreement with Biolojic Design for the development of BD9 to treat atopic dermatitis and asthma.

Related Posts

Rollout of a new malaria vaccine kicks off in Africa

Jan 22, 2024

Advancing parenteral packaging production for the futur...

May 2, 2023

Verve Therapeutics gets grant for gene editing composit...

Aug 23, 2024